Seegene Inc (096530) - Total Liabilities

Latest as of September 2025: ₩214.46 Billion KRW ≈ $145.34 Million USD

Based on the latest financial reports, Seegene Inc (096530) has total liabilities worth ₩214.46 Billion KRW (≈ $145.34 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 096530 operating cash flow to assess how effectively this company generates cash.

Seegene Inc - Total Liabilities Trend (2012–2024)

This chart illustrates how Seegene Inc's total liabilities have evolved over time, based on quarterly financial data. Check 096530 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.

Seegene Inc Competitors by Total Liabilities

The table below lists competitors of Seegene Inc ranked by their total liabilities.

Company Country Total Liabilities
Sunway Co Ltd
SHG:603333
China CN¥797.05 Million
Canadian General Investments Ltd
TO:CGI
Canada CA$202.17 Million
Shenyang Jinbei Automotive Co Ltd
SHG:600609
China CN¥2.29 Billion
Pick N Pay Stores Ltd
JSE:PIK
South Africa ZAC36.82 Billion
Harum Energy Tbk PT
JK:HRUM
Indonesia Rp1.46 Billion
Hangzhou Chinastars Reflective Material Co.Ltd.
SHE:301077
China CN¥682.93 Million
Pearl Global Industries Limited
NSE:PGIL
India Rs15.12 Billion

Liability Composition Analysis (2012–2024)

This chart breaks down Seegene Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 096530 company net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 4.83 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.21 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.18 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Seegene Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Seegene Inc (2012–2024)

The table below shows the annual total liabilities of Seegene Inc from 2012 to 2024.

Year Total Liabilities Change
2024-12-31 ₩223.80 Billion
≈ $151.67 Million
+1.24%
2023-12-31 ₩221.05 Billion
≈ $149.80 Million
-9.03%
2022-12-31 ₩243.01 Billion
≈ $164.68 Million
-40.49%
2021-12-31 ₩408.31 Billion
≈ $276.71 Million
-9.11%
2020-12-31 ₩449.26 Billion
≈ $304.46 Million
+940.74%
2019-12-31 ₩43.17 Billion
≈ $29.25 Million
+20.65%
2018-12-31 ₩35.78 Billion
≈ $24.25 Million
-10.10%
2017-12-31 ₩39.80 Billion
≈ $26.97 Million
-39.37%
2016-12-31 ₩65.65 Billion
≈ $44.49 Million
+11.35%
2015-12-31 ₩58.96 Billion
≈ $39.95 Million
+35.17%
2014-12-31 ₩43.62 Billion
≈ $29.56 Million
-2.19%
2013-12-31 ₩44.59 Billion
≈ $30.22 Million
+7.00%
2012-12-31 ₩41.68 Billion
≈ $28.24 Million
--

About Seegene Inc

KQ:096530 Korea Biotechnology
Market Cap
$767.20 Million
₩1.13 Trillion KRW
Market Cap Rank
#10367 Global
#306 in Korea
Share Price
₩24550.00
Change (1 day)
-2.00%
52-Week Range
₩21850.00 - ₩35150.00
All Time High
₩140042.88
About

Seegene, Inc. manufactures and sells molecular diagnostics products worldwide. It offers IVD products comprising respiratory disease detection products for respiratory infections; gastrointestinal disease detection products for gastrointestinal tract infections; human papillomavirus detection products; sexually transmitted infections causative pathogens detection products; tuberculosis detection … Read more